Avelumab and Merkel Cell Carcinoma: Biological Plausibility of Causation

From General Health Information to Occupational Risk Assessment

The legacy context of americasinfrastructure.org has historically focused on broad public awareness of disease mechanisms and therapeutic interventions, providing a baseline understanding of how biological systems respond to external agents, including pharmaceutical compounds. In mass production environments, particularly those involving biologic drug manufacturing, occupational exposure to active pharmaceutical ingredients becomes a relevant concern. The transition from general health education to occupational risk assessment requires acknowledging that workers in production facilities may encounter concentrated forms of therapeutic agents during handling, formulation, or quality control processes. For Avelumab, a monoclonal antibody used in oncology, the shift from clinical administration to industrial exposure introduces considerations about unintended biological effects in healthy individuals. While clinical contexts emphasize therapeutic benefit-risk profiles, occupational settings demand evaluation of exposure thresholds and potential long-term consequences. This section establishes the foundation for understanding how a therapeutic agent like avelumab might be evaluated for potential causation of disease in an occupational context.

Bridging to Avelumab and Merkel Cell Carcinoma

The bridge concept here connects the legacy of health information with the specific scenario where production workers might face repeated contact with biologic agents, raising questions about immune modulation or cellular responses that differ from therapeutic dosing. This pivot maintains academic neutrality by framing the transition as a logical extension from public health knowledge to industrial hygiene considerations, without venturing into mechanistic claims about disease causation. Avelumab is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/29799096; https://pubmed.ncbi.nlm.nih.gov/33439294). The approval was based on the JAVELIN Merkel 200 phase II trial, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096).

Biological Plausibility of Avelumab Causing Merkel Cell Carcinoma

The biological plausibility of avelumab causing or contributing to MCC is not supported by the available evidence. Avelumab is used as a therapeutic agent for existing MCC, not as a causative factor. The evidence indicates that avelumab functions by blocking PD-L1, thereby enhancing the immune system's ability to attack cancer cells. In the context of MCC, avelumab is administered to patients who already have the disease, and its mechanism of action is to inhibit immune checkpoints that tumors exploit to evade detection. There is no mechanistic pathway described in the evidence linking avelumab to the initiation or development of MCC. Instead, the evidence focuses on avelumab's role in treating MCC and managing refractory cases. For instance, studies have investigated the activity of ipilimumab plus nivolumab in avelumab-refractory MCC, indicating that avelumab is used as a treatment, not a cause (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). Reported adverse effects of avelumab include immune-related adverse events due to overactivation of the immune system. One case report describes hypercalcaemia secondary to reactivation of sarcoidosis in a patient with metastatic MCC on avelumab, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781). This case illustrates that avelumab can trigger immune-related events but does not suggest causation of MCC. The evidence does not document any cases where avelumab caused MCC; rather, it is consistently described as a treatment for the disease.

Risk Considerations and Evidence Summary

Risk considerations regarding adequacy of warnings for avelumab and MCC are informed by the evidence. Avelumab is approved specifically for metastatic MCC, and its prescribing information likely includes warnings about immune-related adverse events, as is standard for checkpoint inhibitors. The evidence does not indicate that warnings about MCC causation are necessary, as avelumab is not implicated in causing the disease. For affected patients, causation-related considerations should focus on the natural history of MCC, which is driven by viral or UV-related factors, not by avelumab exposure. Merkel cell carcinoma is a rare but highly aggressive skin cancer with neuroendocrine differentiation (https://pubmed.ncbi.nlm.nih.gov/36450381). Approximately 80% of MCC cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/34445385). The standard treatment for metastatic MCC includes anti-PD-1/PD-L1 immune checkpoint inhibitors such as avelumab, which show better overall response rates and longer duration of responses compared to conventional chemotherapy (https://pubmed.ncbi.nlm.nih.gov/34445385). Nevertheless, about 50% of patients do not respond or develop immune-related adverse events (irAEs) due to mechanisms such as down-regulation of MHC complexes or induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385). The timeline between exposure and documented harm is relevant only in the context of treatment response or adverse events, not causation. For example, in the JAVELIN Merkel 200 trial, responses were observed after avelumab administration, but this reflects therapeutic effect, not harm (https://pubmed.ncbi.nlm.nih.gov/29799096). In avelumab-refractory patients, subsequent treatments were explored, further emphasizing that avelumab is a treatment option, not a cause of MCC (https://pubmed.ncbi.nlm.nih.gov/33439294; https://pubmed.ncbi.nlm.nih.gov/36450381). In summary, the evidence does not support a causal relationship between avelumab and Merkel cell carcinoma. Avelumab is an established treatment for metastatic MCC, with a mechanism of action that targets PD-L1 to enhance anti-tumor immunity. The biological plausibility of avelumab causing MCC is absent from the literature, and reported adverse events are consistent with immune activation rather than carcinogenesis. Risk considerations should emphasize the therapeutic benefits and known immune-related adverse events of avelumab, without implying causation of MCC.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Can avelumab cause Merkel cell carcinoma?

No, the available evidence does not support a causal relationship between avelumab and Merkel cell carcinoma. Avelumab is a treatment for existing MCC, not a cause. MCC is primarily driven by Merkel cell polyomavirus or UV-induced mutations, not by avelumab exposure.

What is the biological plausibility of avelumab causing cancer?

There is no biological plausibility for avelumab causing MCC. Avelumab works by blocking PD-L1 to enhance the immune system's attack on cancer cells. It does not initiate or promote carcinogenesis. Reported adverse events are immune-related, not carcinogenic.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.